AZD0780 + Ezetimibe + Rosuvastatin + Bempedoic Acid + Placebo
Phase 1Completed 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Dyslipidemia
Conditions
Dyslipidemia
Trial Timeline
Dec 20, 2024 → Oct 29, 2025
NCT ID
NCT06742853About AZD0780 + Ezetimibe + Rosuvastatin + Bempedoic Acid + Placebo
AZD0780 + Ezetimibe + Rosuvastatin + Bempedoic Acid + Placebo is a phase 1 stage product being developed by AstraZeneca for Dyslipidemia. The current trial status is completed. This product is registered under clinical trial identifier NCT06742853. Target conditions include Dyslipidemia.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06742853 | Phase 1 | Completed |
Competing Products
20 competing products in Dyslipidemia